Trial Profile
Re-examination Study for General Vaccine Use to Assess the Safety Profile of Varivax in Usual Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Varicella zoster virus vaccine live (Primary)
- Indications Chickenpox; Varicella zoster virus infections
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 02 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jul 2012 Actual patient number is 729 according to ClinicalTrials.gov.
- 02 Jul 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.